Department of Pediatric Allergy and Immunology, Çiğli Training and Research Hospital, Izmir Bakırçay University, Faculty of Medicine, Izmir, Turkey.
Department of Pediatric Gastroenterology, Çiğli Training and Research Hospital, Izmir, Turkey.
Allergol Immunopathol (Madr). 2023 Jul 1;51(4):40-45. doi: 10.15586/aei.v51i4.872. eCollection 2023.
The aim of this study is to investigate the long-term prognosis of food protein--induced allergic proctocolitis (FPIAP) patients, the risk of developing both allergic and gastrointestinal diseases, and to evaluate whether it leads to allergic march.
A total of 149 children who were diagnosed with FPIAP and developed tolerance at least 5 years prior to the study and 41 children (with no history of food allergy) as a control group were enrolled. Both groups were re-evaluated for allergic diseases as well as gastrointestinal disorders.
The mean age of diagnosis for the FPIAP group was 4.2 ± 3.0 months, while the mean age of tolerance was 13.9 ± 7.7 months. The mean age of both FPIAP and control groups at the last visit was 101.6 ± 24.4 and 96.3 ± 24.1 months, respectively ( = 0.213). At the final evaluation of both groups, the comorbid allergic disease was significantly higher in the FPIAP group ( < 0.001). There was no significant difference between the two groups in terms of functional gastrointestinal disorders (FGIDs), eosinophilic gastrointestinal diseases, and inflammatory bowel disease ( = 0.198, 0.579, and 0.579, respectively).In the FPIAP group, the allergic disease was significantly higher at the final visit in patients with comorbid allergic disease at diagnosis ( < 0.001). In the FPIAP group, FGID was significantly higher in the group that developed allergic diseases in the future, compared to the group that did not develop allergic diseases in the future ( = 0.034). The proportion of both FGID and allergic diseases was significantly higher in subjects that developed tolerance at >18 months, compared to subjects that developed tolerance at >18 months ( < 0.001 and <0.001, respectively).
Patients with FPIAP may develop allergic diseases as well as FGID in the long term.
本研究旨在探讨食物蛋白诱导的过敏性直肠结肠炎(FPIAP)患者的长期预后,以及发生过敏和胃肠道疾病的风险,并评估其是否导致过敏进程。
共纳入 149 例 FPIAP 患儿,他们在研究前至少 5 年已达到耐受状态,另设 41 例(无食物过敏史)患儿作为对照组。对两组患儿均进行过敏性疾病和胃肠道疾病的再评估。
FPIAP 组的诊断年龄为 4.2 ± 3.0 个月,耐受年龄为 13.9 ± 7.7 个月。FPIAP 组和对照组末次随访时的平均年龄分别为 101.6 ± 24.4 个月和 96.3 ± 24.1 个月( = 0.213)。在两组的最终评估中,FPIAP 组的合并过敏性疾病明显更高( < 0.001)。两组间功能性胃肠病(FGIDs)、嗜酸性粒细胞性胃肠病和炎症性肠病的差异均无统计学意义( = 0.198、0.579 和 0.579)。在 FPIAP 组中,与初诊时合并过敏性疾病的患者相比,在最终随访时,合并过敏性疾病的患者明显更高( < 0.001)。在 FPIAP 组中,与未发生未来过敏疾病的患者相比,未来发生过敏疾病的患者 FGID 明显更高( = 0.034)。与 18 个月内达到耐受的患者相比,18 个月以上达到耐受的患者 FGID 和过敏疾病的比例均明显更高( < 0.001 和 <0.001)。
FPIAP 患者可能会在长期内发生过敏和 FGID。